The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! The stock decreased 6.73% or $0.35 on November 23, hitting $4.85. About 2.11M shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 78.04% since April 22, 2016 and is downtrending. It has underperformed by 83.45% the S&P500.
The move comes after 7 months negative chart setup for the $190.79M company. It was reported on Nov, 24 by Barchart.com. We have $4.46 PT which if reached, will make NASDAQ:DVAX worth $15.26M less.
Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on March, 14. They expect $-0.86 earnings per share, down 22.86% or $0.16 from last year’s $-0.7 per share. After $-0.90 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -4.44% EPS growth.
Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage
Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Zacks upgraded Dynavax Technologies Corporation (NASDAQ:DVAX) on Wednesday, August 12 to “Hold” rating. The firm has “Sector Perform” rating given on Thursday, April 28 by RBC Capital Markets. The stock has “Neutral” rating given by JP Morgan on Wednesday, April 27. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Outperform” rating given on Monday, November 30 by RBC Capital Markets.
According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”
Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.26, from 1.02 in 2016Q1. The ratio is positive, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Great West Life Assurance Com Can last reported 3,673 shares in the company. Pnc Fin Service Group has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Rhenman Partners Asset Mgmt, a Sweden-based fund reported 150,000 shares. Moreover, State Board Of Administration Of Florida Retirement System has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 15,836 shares. Moreover, Bnp Paribas Arbitrage has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 1,631 shares. Moreover, Manufacturers Life Ins The has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 27,406 shares. Ubs Asset Americas owns 538,423 shares or 0.01% of their US portfolio. Goldman Sachs Grp Inc owns 480,802 shares or 0% of their US portfolio. The Massachusetts-based Boston Partners has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Blackrock Inc accumulated 3,490 shares or 0% of the stock. Deutsche Bancshares Ag accumulated 0% or 391,982 shares. Moreover, American Century Companies has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 72,902 shares. Cubist Systematic Strategies Limited Liability Corp has 0% invested in the company for 252 shares. Blackrock Japan has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Bancshares Of Montreal Can has 2,066 shares for 0% of their US portfolio.
More important recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Businesswire.com which released: “SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit …” on November 19, 2016, also Prnewswire.com published article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …”, Investorplace.com published: “Why Dynavax Technologies Corporation (DVAX), Petroleo Brasileiro SA Petrobras …” on November 14, 2016. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) was released by: 247Wallst.com and their article: “Why Dynavax Shares Are in Freefall” with publication date: November 14, 2016.
DVAX Company Profile
Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.